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REVIEW ARTICLE
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ABSTRACT
Background: New, complex, and expensive therapies targeting Interleukin-5 (IL-5) to treat severe
eosinophilic asthma are emerging.
Objective: To assess efficacy, adverse events, and inter-drug comparison of mepolizumab and
reslizumab for treating severe eosinophilic asthma.
Design: A systematic review and meta-analysis on randomized, placebo-controlled, clinical trials
elucidating two critical (exacerbation rate and oral corticosteroid (OCS) use) and six important
clinical outcomes on the efficacy and safety of mepolizumab and reslizumab.
Results: Five studies (N = 2197) contributed with data for exacerbation rate, showing a reduction
of 53% (95% CI 46; 59) in favour of anti-IL-5, corresponding to –0.94 annual exacerbations (95% CI
–1.08;–0.82), thus exceeding the predefined minimal clinical important difference (MCID) of 25%
reduction of the estimated ≥2 annual exacerbations. Quality of evidence was considered moder-
ate, with low heterogeneity in study findings (I2 = 0%). One study (N = 135) contributed with data
on percentage of patients experiencing ≥50% reduction inoral corticosteroid treatment, showing
an effect of 20% (95% CI 2.3;47) in favour of anti-IL-5 treatment (mepolizumab), thus exceeding
the predefined MCID of 10%. Quality of evidence was considered low.
Compared to placebo, anti-IL-5 showed significant improvements in lung function, asthma control, and
asthma-related quality of life, but below the MCIDs. No differences were observed for serious adverse
events and number of patients, who dropped out. No studies evaluating sickleave or head-to-head
comparisons were identified. By indirect comparison, we found no significant difference between
mepolizumab and reslizumab in any ofthe predefined clinical outcomes. OCS treatment reduction
could not be compared due to lack of reslizumab studies investigating this outcome.
Conclusions: Mepolizumab and reslizumab provide significant and clinically relevant improve-
ments in exacerbation rate and OCS reduction. Indirect, inter-study comparisons revealed no
differences between the anti-IL-5 drugs in efficacy or safety measures.
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Background
Asthma is a common chronic inflammatory airway disor-
der affecting 300 million people worldwide [1]. Severe
asthma is defined by frequent exacerbations despite treat-
ment with high-dose inhaled corticosteroids (ICS) plus a
second controller, or the need for daily oral corticosteroid
treatment (OCS), to prevent exacerbations and achieve
proper asthma control or stay uncontrolled on this treat-
ment [2,3]. The prevalence of severe asthma is estimated
3–15% of all patients with asthma, depending on the
method of identification [4] and is associated with a sig-
nificant negative impact on quality of life for the affected
patients [5], as well as an increased risk of morbidity and
mortality [6]. The uncontrolled severe asthma patient is a
smaller part of the severe asthma patients, estimated one-
third of all severe asthma patients [7].
Asthma has traditionally been categorised as either
allergic- or non-allergic. However, it is now increasingly
recognised that asthma is a heterogeneous syndrome
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consisting of several immunological subtypes with differ-
ing disease mechanisms, which has opened an avenue for
personalised pharmacological treatment targeting these
endotypes [8]. A well-defined disease endotype is eosino-
philic asthma, where an increased concentration of eosi-
nophil granulocytes in the blood and bronchial mucosa
leads to release of pro-inflammatory mediators, causing
bronchial hyperresponsiveness and poorly controlled
asthma [8]. The first specific treatment to target eosinophil
asthma was mepolizumab, marketed in Europe in 2015.
Subsequently, reslizumab was approved and marketed in
2016.
Both treatments are humanised IgG monoclonal anti-
bodies with a high affinity for interleukin-5 (IL-5), neu-
tralising IL-5 by binding to epitopes on the IL-5-Rα-
binding domain [9]. Both mepolizumab and reslizumab
have picomolar affinity in inhibiting IL-5 activity, which
practically neutralises the molecular target [10].
Both treatments have shown beneficial effects in
randomised controlled trials of severe eosinophilic
asthma with the potential to halve the rate of asthma
exacerbations. However, a more broad evaluation of
the clinical benefits as well as a comparison of the
two anti-IL-5 treatments is lacking.
Therefore, in spring 2016 the Danish Medicines
Council initiated this systematic review andmeta-analysis
on the efficacy and adverse events of the two anti-IL-5
medicines, mepolizumab and reslizumab, in order to
assess the evidence of clinical effects and to assess whether
one anti-IL-5 treatment was superior to the other for
treating severe uncontrolled eosinophilic asthma.
Methods
The Danish Medicines Council appointed an Expert
Committee, which included clinicians in respiratory
diseases, paediatrics, and clinical pharmacology, as
well as clinical pharmacists, and patient representa-
tives. Assisted by the Danish Medicines Council
Secretariat, the Expert Committee initially developed
a protocol defining the clinical questions, structured as
PICO (Patient, Intervention, Comparator, Outcome)
questions and defined the minimal clinically important
differences between treatment and placebo or between
the two anti-IL-5 medicines [11]. The Secretariat aided
with the literature search, selection of relevant papers,
data-extraction, and data analysis.
Protocol and registration
This systematic review and meta-analysis is reported in
accordance with the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses: The PRISMA
Statement [12]. The protocol was developed before the
literature search was conducted following the Danish
Medicines Councils method handbook [13]. The pro-
tocol and final report have been published in Danish
on the Danish Medicines Councils website [14,15].
Eligibility criteria
We conducted a literature search involving all studies of
adults (≥18 years) with asthma treated with mepolizumab
or reslizumab, to answer the predefined PICO questions:
(1) Which adult patients with severe eosinophilic
asthma should be offered anti-IL-5 therapy?
a. Population – Patients ≥18 years of age with
severe, eosinophilic asthma. The patient popula-
tion was not specified further, because the results
from the literature search were anticipated to
answer which patient characteristics would qua-
lify for anti-IL-5 therapy.
b. Intervention – Anti-IL-5 therapy (reslizumab
3 mg/kg intravenous administration every
4 weeks, or mepolizumab fixed dose 100 mg sub-
cutaneous administration every 4 weeks) on top
of standard care.
c. Comparator – Placebo on top of standard care.
d. Outcome(s) (minimal clinical important differ-
ence [MCID]) – Of critical importance: excacer-
bation rate (a reduction in annual rate of at least
25%, corresponding to a minimum reduction of
0.5 excerbations per year); OCS (1) average
%-reduction in daily dose [maintenance-treat-
ment] (at least 20% and at least 2.5-mg predni-
solone-equivalent dose), (2) percentage of
patients who discontinued OCS (a minimum of
5%-points, (3) percentage of patients who
achieve a ≥50% reduction of OCS dose (a mini-
mum of 10%-points). Please refer to Table 1 for
definitions of outcomes considered important,
and less important.
(2) Is there clinically relevant difference between
mepolizumab and reslizumab in the treatment of
patients with severe, eosinophilic asthma?
a. Population – Patients ≥18 years with severe, eosi-
nophilic asthma.
b. Intervention – Reslizumab 3 mg/kg intravenous
administration every 4 week on top of standard
care.
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c. Comparator – Mepolizumab fixed dose of 100-
mg subcutaneous administration every 4 weeks
on top of standard care.
d. Outcome(s) (MCID) – of critical importance:
excacerbation rate (a reduction in annual rate of
at least 25%, corresponding to a minimum reduc-
tion of 0.5 excerbations per year); OCS (1) aver-
age %-reduction in daily dose [maintenance-
treatment] (at least 20% and at least 2.5-mg pre-
dnisolone-equivalent dose), (2) percentage of
patients who discontinued OCS (a minimum of
5%-points, (3) percentage of patients who
achieve a ≥50% reduction in OCS dose (a mini-
mum of 10%-points) (Table 1).
The approved dose of mepolizumab is 100 mg admi-
nistered subcutaneously, whereas some studies exam-
ined 75-mg intravenous injections. However, since
100-mg subcutaneous and 75-mg intraveneous mepo-
lizumab are considered equipotent doses, we included
studies of both. We excluded studies examining other
doses than the above as they have not been approved as
standard therapy in the EU, according to mepolizu-
mab’s summary of products characteristics [16]. We
used the Danish Society of Respiratory Medicines defi-
nition, evaluation, and treatment of severe asthma,
which is based on the international ERS/ATS guide-
lines [2,17].
Information sources
To identify eligible systematic reviews and randomised
controlled trials, we searched MEDLINE, Embase, and
relevant databases from the Cochrane Library (see
Supplementary Appendix Table 1 for detailed search
strings). In MEDLINE, all available databases were
searched so that records not yet MEDLINE-indexed
were identified. In the Cochrane Library, the databases
Cochrane Database of Systematic Reviews (CDSR),
Cochrane Central Register of Controlled Trials
(CENTRAL), and Database of Abstracts of Reviews of
Effects (DARE) were searched.
Table 1. List of outcome measures. For each outcome measure, the importance is indicated, and for critical and important outcome
measure the minimal clinically important difference is reported.
Outcome measures Importance Measure unit
Minimal clinically important
difference
Mortality Critical*
Exacerbation rate Critical Average reduction in the annual number of exacerbations 25% (a minimum reduction of
0,5 exacerbations per year)
Number of patients who experience 0 exacerbations annually 10 percentage points
Oral corticosteroid-
maintenance
treatment
Critical Average %-reduction in daily dose (maintenance-treatment) 20% (at least 2.5-mg
prednisolone equivalent
dose)
Percentage of patients who are discontinued oral corticosteroid-maintenance
treatment
5 percentage points
Percentage of patients who experience ≥50% reduction of oral corticosteroid
treatment
10 percentage points#
Lung function FEV1 Important Average change in lung function 200 ml
Percentage of patients who experience an improvement of 200 ml or more 15 percentage points
Asthma control Important Average change in asthma control. A prioritised list of scores:
· ACQ 5 (Asthma Control Questionnaire)
· ACT (Asthma Control Test)
· Other similar questionnaires
ACQ: 0.5
ACT: 3
Quality of life (QoL) Important Average change in QoL. A prioritised list of scores:
· Astma Quality of Life Questionnaire (AQLQ)
· Other questionnaires
AQLQ: 0.5 points
Serious adverse
events (SAEs)
Important The added number of SAEs 5 percentage points for the
added number of SAEs
Specific subgroups of SAEs, including anaphylaxis is assessed if they are distributed
uniformly between the groups
No minimal clinically
important difference is
reported
Dropout rate Important The percentage of patients who dropped out when the study was completed
(difference between intention-to-treat population and patients who completed
the study)
10 percentage points
Sick leave Important Average number of sick leave days per year 5 days per year
Eosinophil count Less Eosinophils per microL
Adverse events (AEs) Less The added number of AEs
* Mortality is always considered to be a critical effect goal, albeit not an effective efficacy measure in the assessment of biological drugs in severe asthma. Asthma-
related death occurs rarely, and it is therefore not estimated that outcome measure will provide any relevant information. In relation to safety, it is included in
outcome measure: serious adverse events (SAEs). Mortality will therefore not act as a separate outcome measure in the assessment of the therapy.
# The Expert Committee defined this outcome measure after the protocol was approved as data could not be extracted for the average OCS reduction. FEV1
= forced expiratory volume
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We also searched the following databases to identify rele-
vant clinical guidelines: National Guidelines Clearinghouse,
Guidelines International Network, National Institute for
Health and Care Excellence, Cochrane Library Technology
Assessments (HTA), and the Danish Society of Respiratory
Medicine. Market authorisation holders and members of the
Expert Committee could also contribute with relevant
literature.
Search
Searching MEDLINE and Embase, we identified sys-
tematic reviews using the built-in ‘Systematic review’
filter. For identification of randomised controlled
trials, a customised filter with high sensitivity was
used. No publication language or date limits were
applied. The search strategy was developed based on
input from all Expert Committee members by an
information specialist from the Danish Medicines
Council secretariat (see Supplementary Appendix
Table 1 for the complete search strings with annota-
tions). The searches were conducted on 15 June 2017.
Initially, the search strategy was designed also to
include identification of records solely mentioning
omalizumab. However, according to the eligibility
criteria only records mentioning reslizumab and/or
mepolizumab were considered possibly relevant.
Manual screening of reference lists of the identified
studies was carried out by at least two members of the
Expert Committee and the secretariat. References not
already identified in the initial search were screened by
full text reading.
Study selection
Two persons from the Danish Medicines Council’s
secretariat independently screened the identified guide-
lines and assessed whether they were relevant to answer
the PICO questions. The same two independently
screened the identified systematic reviews and rando-
mised controlled trials on title and abstract level. Next,
they independently screened the selected systematic
reviews on full-text level and assessed whether they
met the predefined criteria for inclusion. The selected
randomised controlled trials were screened on full-text
level by one of the aforementioned two and at least one
Expert Committee member. Any disagreements were
resolved by consensus-based discussion.
Data collection process and data items
After the study selection process was finalised, all rele-
vant data were extracted by one person and validated
by another. Bibliographical and study description data,
patient characteristics, and data related to the primary
and secondary outcomes were extracted from the
included studies.
Before the search and data extraction, the out-
comes were classified as ‘critical’, ‘important’, and
‘less important’ depending on the clinical relevance
of the outcome measure. By consensus by the
Expert Committee members, measure units were
identified, as well as the MCIDs. MCIDs were cho-
sen based on previously validated thresholds, where
possible [18].
Predefined subgroup analysis included sex, age, age
at asthma onset, blood eosinophil count, nasal polypo-
sis present, inhalation allergy present, and treatment
intensity according to Global Initiative for Asthma
(GINA) (in order to assess the criteria for initiating
anti-IL-5 therapy) [1]. The subgroup analyses were not
included in the meta-analysis, but were described
narratively.
Risk of bias in individual studies
Two persons from the Danish Medicines Council’s
secretariat independently assessed the methodological
quality of eligible studies using the Cochrane collabora-
tion’s tool for assessing risk of bias. The assessment
included evaluation of risk of bias across the following
six domains: sequence generation, allocation conceal-
ment, blinding (of participants, personnel, and out-
come assessors), incomplete outcome data, selective
outcome reporting, and other sources of bias. The
final judgement was categorised into low, high, or
unclear risk of bias [19].
Summary measures and synthesis of results
The evidence of each clinical question was examined
and is presented per outcome measure. We used inten-
tion-to-treat analyses with hazard ratios (HR), relative
risks, rate ratios, or odds ratios (OR) for dichotomous
outcome measures. For continuous outcome measures,
we used mean difference (MD) or standardised mean
difference (SMD). We did not impute missing data.
The meta-analyses were conducted with the inverse
variance method with the assumption of random
effects. For indirect comparisons of the effect of mepo-
lizumab vs. reslizumb, Bucher’s method for adjusted
indirect comparison was used [20]. Statistical test for
heterogeneity was performed (Cochran’s Q) and degree
of heterogeneity was described with the I2 statistic.
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Confidence in cumulative evidence
We used the Grading of Recommendations Assessment,
Development and Evaluation (GRADE) approach to
assess the quality of evidence provided by the meta-
analyses [21]. The following domains were evaluated:
study design, risk of bias, inconsistency, indirectness,
imprecision, and other considerations. The secretariat
conducted the systematic GRADE-based assessment of
the literature, with input from the Expert Committee.
Depending on the basic design of the included studies
and any subsequent downgrading, the evidence quality
was categorised as high, moderate, low, or very low.
Results
Study selection
Guidelines and systematic reviews
A total of 2 clinical guidelines and 10 systematic reviews
with potential relevance of answering the predefined
PICO questions were identified (see Supplementary
Appendix Table 2). None of these had direct transfer-
ability to answer the PICO questions, and were not
included for further analysis.
Primary literature
The systematic literature search identified four rando-
mised controlled trials which examined the efficacy of
mepolizumab [22–25], and five trials (published in four
papers) which examined the efficacy of reslizumab [26–
28]. All studies had placebo as comparator. The paper
by Castro et al. described two duplicate randomised
controlled trials [29]. In the subsequent paragraphs, we
have named study 1 Castro 2015a, and study 2 Castro
2015b. The study by Bel et al. [25] was not included in
the meta-analysis because the study design differed
significantly from the other studies. The results from
Bel et al. were instead described for each outcome.
We received 25 papers from the marketing authorisa-
tion holders. Twenty-three studies were already identi-
fied, one study was excluded due to the wrong study
design, and one study that was published after the litera-
ture search was conducted was assessed on full-text level
as it contained relevant subgroup analyses.
Five studies that included relevant subgroup analysis
were identified, three regarding mepolizumab [30–32],
and two regarding reslizumab [33,34]. In total, we
included 13 studies for further analysis, and eight of
those were included in the meta-analysis (see literature
selection flow chart in Figure 1).
Study characteristics
The study characteristics varied significantly between
the included studies, especially in regard to design (ran-
domised double-blind, placebo-controlled trials with
single- or multiple phases; randomised double-blind
double-dummy placebo-controlled studies), follow-up
length (range from 15 to 52 weeks), intensity of the
standard of care asthma therapy (all mepolizumab stu-
dies included patients with a treatment-intensity equal-
ling severe asthma whereas the majority of all
reslizumab studies included patients with a treatment
intensity equalling moderate to severe asthma), eosino-
phil count at treatment initiation (mepolizumab: 150–
300 eosinophils per microL depending on the time of
measurement; the majority of reslizumab studies
included patients with ≥400 eosinophils per microL,
and one study included patients with ≥3% sputum eosi-
nophils), and number of previous exacerbations (from
no previous exacerbations to a minimum of two).
Heterogeneity in results was examined in terms of dif-
ference in design and characteristics. An overview of the
included studies is presented in the Supplementary
Appendix Tables 3 and 4.
Synthesis of results
Exacerbations
Average reduction in the annual number of
exacerbations
Combined. In total, five randomised trials reported in
four papers [22–24,29] comprising a total of 2197
patients were included in the meta-analysis. The
rate ratio for the number of annual exacerbations
showed a favourable effect in the anti-IL-5 group
compared to placebo (rate ratio 0.47 [95% CI 0.41;
0.54), which can be translated into an absolute risk
reduction of 53% (95% CI 46; 59) (Figure 2). The
absolute annual effect on exacerbations was −0.94
yearly exacerbations (95% CI −1.08; −0.82) in favour
of the anti-IL-5 group compared to placebo, calcu-
lated based on an estimate of the annual exacerbation
rate in Danish patients eligible for anti-IL-5 treat-
ment of minimum of two exacerbations per year
(Table 2). This effect was larger than the predefined
MCID of 25% (a minimum reduction of 0.5 exacer-
bations per year). The heterogeneity was low
(I2 = 0%, p = 0.80) and quality of evidence was
considered moderate.
Mepolizumab. Three studies were included comprising
1244 patients [22–24]. The rate ratio of annual exacer-
bations was 0.47 [95% CI 0.40; 0.56] in favour of the
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mepolizumab group compared to placebo. The hetero-
geneity was low (I2 = 0%).
Reslizumab. Two RCTs reported in the same paper
were included comprising 953 patients [29]. The rate
ratio of annual exacerbations was 0.46 [95% CI 0.37;
0.59] in favour of the reslizumab group compared to
placebo. The heterogeneity was low (I2 = 0%).
Number of patients who experience 0 exacerbations
annually
Combined. In total, four randomised trials reported in
three papers comprising a total of 1837 patients were
included in the meta-analysis. We found a relative
improvement of 1.42 (95% CI 1.3; 1.56) on the percen-
tage of patients experiencing 0 exacerbations in favour
Figure 1. Flow chart of literature selection.
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of the anti-IL-5 group (Figure 3). The calculated abso-
lute difference was 16.9% (95% CI 12.1; 22.5) compared
to placebo, which can be translated to 40 out of 100
who experience 0 exacerbations in the placebo group
compared to 57 out of 100 in the anti-IL-5 group
(Figure 4). This was larger than the predefined MCID
of 10 percentage points. The heterogeneity was low
(I2 = 0%, p = 0.48) and quality of evidence was con-
sidered moderate.
Mepolizumab. Two studies were included comprising 884
patients [22,24,25]. The relative improvement was 1.58 (95%
CI 1.33; 1.87) on the percentage of patients experiencing 0
exacerbations in favour of the anti-IL-5 group. The hetero-
geneity was considered low (I2 = 0, p = 0.56).
Reslizumab. Two RCTs reported in the same paper
were included comprising 953 patients [29]. The rela-
tive improvement was 1.36 (95% CI 1.22; 1.52) on the
percentage of patients experiencing 0 exacerbations in
favour of the anti-IL-5 group. The heterogeneity was
considered low (I2 = 0, p = 0.99).
The subgroup analyses showed that the degree of
blood eosinophilia, number of previous exacerbations,
and the intensity of underlying asthma treatment could
have an influence on the effect of the anti-IL-5 treatment.
Subgroup analyses show that the effect of anti-IL-5 treat-
ment is more pronounced in late-onset asthma compared
to early-onset (see Supplementary Appendix – subgroup
analysis, narrative overview for details).
Figure 2. Rate ratio for annual exacerbation rate.
Table 2. Summary of main results.
Relative effect from
meta-analysis
Calculated absolute
effect
Minimal clinically
important relative effect
Minimal clinically
important absolute effect
Annual exacerbation rate 53% reduction (95%
CI: 46; 59 %)
−0.94 (95% CI −1.08;
−0.82)
25% 0.5 exacerbations
Number of patients who experience 0
exacerbations annually
Risk ratio: 1.42 (95%
CI 1.30; 1.56)
16.9%-points (95% CI
12.1; 22.5)
- 10%-points
Average %-reduction in daily dose OCS NA NA 0.2 2.5-mg prednisolone
equivalent
Percentage of patients who experience ≥50%
reduction OCS
1.61 (95% CI 1.07–
2.41)
20.3%-point (95% CI
2.3; 47.0)
- 10%-points
Percentage of patients who are discontinued
OCS
1.91 (95% CI 0.69;
5.30)
6.9%-point (95% CI
−2.3–32.6)
- 5%-points
Average change in FEV1 - 112.9 ml (95% CI: 82.4;
143.4)
- 200 ml
Percentage of patients who experience an
improvement of 200 ml or more
NA NA - 15%-points
Average change in ACQ - −0.29 point (95% CI: –
0.36; – 0.23)
- ACQ: 0.5
Average change in AQLQ - 0.32 point (95% CI:
0.22; 0.43)
- AQLQ: 0.5
Percentage of patients who experience SAE 0.73 (95% CI: 0.57;
0.92)
−2.4%-point (95% CI:
−0.7; −3.8)
- 5%-points
Percentage of patients dropout 0.85 (95% CI: 0.69;
1.05)
−2.3%-point (95% CI:
−4.7; 0.7).
- 10%-points
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Oral corticosteroid (OCS) treatment
Median reduction and percentage of patients who
experienced ≥50% reduction of OCS. A single rando-
mised study (n = 135) of mepolizumab was included for
further analysis [25], which showed a median reduction of
OCS of 50% (95% CI 20; 75) compared to a 0% (95% CI
−20; 33.3) reduction in the placebo group. Due to the lack
of statistical evaluation of the average reduction in OCS
between mepolizumab and placebo, it was not possible to
assess the predefined MCID of 20%. Instead, we assessed
the percentage of patients, who experienced ≥50% reduc-
tion in OCS treatment. The relative difference was 1.61
(95%CI 1.07; 2.41) in favour ofmepolizumab (22/66 in the
placebo group experienced a ≥50% reduction in OCS
compared to 37/69 in the mepolizumab group)
(Figure 5). We calculated an absolute effect of 20.3%-
points (95% CI 2.3; 47.0), which was larger than the
defined MCID of 10 percentage points. The quality of
evidence was considered low.
Percentage of patients who were discontinued OCS. In
the mepolizumab group, 10 out of 69 patients were dis-
continued OCS, whereas 5 out of 66 were discontinued
OCS in the placebo group, which accounted for a relative
difference of 1.91 (95% CI 0.69; 5.30) in favour of the
mepolizumab group. This yielded a 6.9% (95% CI −2.3;
32.6%) in favour ofmepolizumab (Figure 6). The quality of
Figure 3. Risk ratio for percentage of patients who experience 0 exacerbations.
Figure 4. Cates plot illustrating percentage of patients who experience 0 exacerbations. The Cates plot is based on the absolute
effect calculated by the median for the control non-event rate in the included studies (40.2%). This gives a difference of 16.9%-
points in the percentage of patients who experience 0 exacerbations.
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Figure 5. Cates plot of patients who experienced ≥50% reduction in oral corticosteroid treatment. The Cates plot is based on the
absolute effect calculated by the median for the control non-event rate in the included studies (33%). This gives a difference of
20.3%-points in the percentage of patients who experience ≥50% reduction in oral corticosteroid treatment.
Figure 6. Cates plot of patients who discontinued oral corticosteroid-maintenance treatment. The Cates plot is based on the
absolute effect calculated by the median for the control non-event rate in the included studies (7.6%). This gives a difference of
6.9%-points in the percentage of patients who discontinue oral corticosteroid-maintenance treatment.
Figure 7. Mean difference lung function, FEV1.
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evidence was considered low. We found no studies on the
reduction in OCS when using reslizumab. The quality of
evidence was considered low.
Lung function
Nine randomised trials of 3160 patients were included
in the meta-analysis (four regarding mepolizumab [22–
25], and five regarding reslizumab [26–29]). No studies
presented the number of patients experiencing the
MCID of 200 mL in forced expiratory volume
(FEV1). We found an absolute difference of FEV1 of
112.93 ml (95% CI 82.44; 143.31) in favour of the anti-
IL-5 treatment compared to placebo (Figure 7), which
is below the minimal clinically important difference.
We found no significant heterogeneity (I2 = 0%,
p = 0.44). The quality of evidence was considered
moderate.
Asthma control
Nine studies of 3165 patients were included; four mepoli-
zumab studies (three using Asthma Control Questionnaire
[ACQ]5 [22,23,25], and one ACQ6 [24]), and reslizumab
studies (all used ACQ7 [26–29]). We pooled the results
from the different ACQ versions in the meta-analysis and
found a change of −0.29 points (95%CI−036;−0.23) in the
anti-IL-5 group compared to placebo, which was below the
minimal clinically important effect of 0.5 points (Figure 8).
No significant heterogeneity was observed (I2 = 6%,
p = 0.38). The quality of evidence was considered low.
Quality of life
We included four studies using the Asthma Quality of Life
Questionnaire (AQLQ): one mepolizumab study [24] and
three reslizumab studies [26,29]. Further three studies were
included, which used SGRQ, in which the MCID is 4 points
[22,23,25], which gave a total of 2562 included patients. We
pooled all the results by recalculating the scores to SMD and
found a significant improvement of quality of life among
patients in the anti-IL-5 group compared to the placebo
group (SMD 0.32 [95% CI 0.22; 0.43). We thereafter back-
transformed the SMD to AQLQ points by assuming a SD of
1 (the SD was observed to be 0.88–1.12), which showed an
Figure 8. Mean difference in asthma control (ACQ).
Figure 9. Standardised mean difference in quality of life.
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improvement of 0.32 (95% CI 0.22; 0.43) in the anti-IL-5
group compared to placebo (Figure 9) that was below the
MCID of a 0.5 point improvement. Moderate heterogeneity
(I2 = 43%) was observed, but this was not significant
(p = 0.12). The quality of evidence was considered low.
Dropout rate
We included nine studies of 3201 patients (four
regarding mepolizumab [22–25], and five regarding
reslizumab [26–29]), and found a larger dropout rate
in the placebo group compared to the anti-IL-5
group (relative risk reduction of 0.85 [95% CI 0.69;
1.05]). Recalculated to absolute values, we found
−2.3%-point (95% CI −4.7;-0.7) difference in dropout
in the anti-IL-5 group compared to the placebo
group (Figure 10), which was below the MCID of
10%. We found no significant heterogeneity
(I2 = 0%, p = 0.28). The quality of evidence was
considered moderate.
Serious adverse events (SAE)
We included nine studies of 3193 patients (four regard-
ing mepolizumab [22–25], and five regarding reslizu-
mab [26–29]), and found an increased risk of SAE in
the placebo group compared to the anti-IL-5 group
with a relative risk reduction of 0.73 [95% CI 0.57;
Figure 10. Relative risk for dropout.
Figure 11. Risk ratio for serious adverse events.
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0.92] in favour of the anti-IL-5 group. This was recal-
culated to an absolute value of −2.4%-points (95% CI
−0.7; −3.8) (Figure 11). The effect estimate was not
greater than that MCID of ±5% points. The effect was
positive for anti-IL-5 treatment and therefore it did not
imply a negative impact on the assessment of the
medicines. We found no significant heterogeneity
(I2 = 0%, p = 0.67). The quality of evidence was con-
sidered moderate.
Sick leave
We found no studies evaluating the effect of anti-IL-5
treatment on sick leave.
Risk of bias evaluation
In general, the risk of bias assessed by the Cochrane Risk
of Bias Tool was considered low: two studies did not
account for random sequence generation or allocation
concealment [26,28] and one study did not account for
blinding of outcome assessment [24]. A detailed assess-
ment of the quality of evidence (GRADE) is presented in
the Supplementary Appendix Table 5.
Comparison of the effect of mepolizumab and
reslizumab
Using Bucher’s method of indirect comparison
between two effects, we found no significant difference
between mepolizumab and reslizumab in any of the
predefined clinical outcomes (Tables 3 and 4).
It was not possible to compare the effect on reduction
in OCS usage because no studies on reslizumab were
published before conducting the bibliographic search.
For a detailed overview of the quality of evidence, please
refer to Supplementary Appendix Table 6.
Discussion
Summary of the evidence
In this systematic review and meta-analysis of the
efficacy and adverse events of the two direct anti-IL-5
treatments, mepolizumab and reslizumab, we found no
clinically relevant inter-drug differences in efficacy for
any of the 8 predefined critical and important clinical
outcomes.
Compared to placebo, both mepolizumab and reslizu-
mab had statistically significant and clinically relevant
impact on the exacerbation rate in the meta-analysis.
The effect compared to placebo on the reduction in
annual exacerbations was pronounced with a 53% abso-
lute risk reduction. In addition, the absolute difference in
patients experiencing 0 exacerbations was 16.9 percen-
tage points with 40 out of 100 who experienced 0 exacer-
bations in the placebo group compared to 57 out of 100 in
the anti-IL-5 group.Mepolizumab further showed a clini-
cally relevant reduction in OCS maintenance doses com-
pared to placebo with 20.3 percentage points more in the
mepolizumab group being able to halve their mainte-
nance OCS dose, but evidence was not available for
reslizumab on that outcome. For both anti-IL-5 drugs,
the meta-analysis showed statistically significant effects
on lung function, asthma control, asthma-related quality
of life, and occurrence of SAEs, but with differences
below the prespecified MCIDs.
Generally, the quality of evidence was very low
concerning our primary aim of studying inter-drug
differences, as only indirect comparison was available
due to lack of published studies comparing the drugs
head-to-head. The quality of evidence was low to mod-
erate regarding the comparisons of mepolizumab and
reslizumab with placebo, and with a low risk of bias.
Our results align with a recent Cochrane review by
Farne et al., which also included the newly approved
Table 3. The effect of mepolizumab and reslizumab – continuate endpoints.
Absolute measures
Mepolizumab vs. placebo
[95% CI]
Reslizumab vs. placebo
[95% CI] Mepolizumab vs. reslizumab [95% CI]
Lung function FEV1 Mean difference 99.11 [52.80; 145.41] 125.63 [76.73; 174.54] −26.52 [−93.87; 40.83]
Asthma control questionnaire ACQ Mean difference −0.34 [−0.50; −0.19] −0.26 [−0.34; −0.18] −0.08 [−0.25; 0.09]
Quality of life (AQLQ and SGRQ) SMD 0.33 [0.11; 0.55] 0.30 [0.18; 0.42] 0.03 [−0.22; 0.28]
Table 4. The effect of mepolizumab and reslizumab – dichotome endpoints.
Relative measures (log scale)
Outcome
measure
Mepolizumab vs.
placebo [95% CI]
Reslizumab vs.
placebo [95% CI] ARR = absolute risk reduction
Res (Control) Mep (Exp) ARR [95% CI]
Annual exacerbation Rate ratio 0.47 [0.40; 0.56] 0.46 [0.37; 0.59] 0,0200 0,0204 −0,04 [−0.73; 0.47]
Number of patients who experience 0
exacerbations annually
Risk ratio 0.71 [0.63; 0.80] 0.64 [0.52; 0.78] 0,6851 0,7600 −7.49 [−27.66; 8.44]
Serious adverse events Risk ratio 0.66 [0.48; 0.91] 0.81 [0.57; 1.14] 0,0405 0,0330 0.75 [−1.24; 1.99]
Dropout Risk ratio 0.78 [0.48; 1.27] 0.87 [0.68; 1.12] 0,1293 0,1159 1.34 [−7.10; 6.22]
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IL-5-receptor antagonist benralizumab, showing a
reduction in asthma exacerbations of almost one half
in the anti-IL-5 group compared to placebo [35]. Like
our meta-analysis, Farne et al. also observed a modest
improvement in quality of life and a small improve-
ment in lung function in both mepolizumab- and resli-
zumab-treated patients. The clinical outcomes in our
study were comparable to the outcomes investigated by
Farne et al., except that we included OCS maintenance
dose reduction and discontinuation as critical out-
comes, because the risk of serious adverse events are
substantial with such treatment regimen [36].
Importantly, the study by Farne et al., although largely
including the same studies, does not provide an inter-
drug comparison of efficacy and safety.
Inter-drug comparison
We did not identify any head-to-head studies of resli-
zumab vs. mepolizumab, but using indirect compari-
sons we observed comparable effects for all of the
predefined critical and important outcomes. This was
affirmed by the fact that heterogeneity for the critical
and important outcomes in the combined analyses of
mepolizumab vs. placebo and reslizumab vs. placebo
was deemed low. However, the evidence is considered
low with respect to the critical outcome measures, due
to the indirect comparison and the lack of studies of
reslizumab on reduction in OCS maintenance treat-
ment. Still, given that the pharmacological profiles of
the two medicines are comparable [10], we would
expect reslizumab to have a beneficial effect on reduc-
tion in OCS treatment comparable to that observed for
mepolizumab. It is important to emphasise that no
studies have been published on this topic yet, and the
derived conclusion are based on low-grade evidence.
Inter-study differences
Key points of asthma severity and cut-off for blood
eosinophil level differed between studies on the two
anti-IL-5 drugs. The majority of the reslizumab studies
included patients with moderate asthma, where the use
of a second controller was not mandatory [26,28,29].
This is against current asthma treatment guidelines,
where the systematic assessment in the GINA criteria
clearly states that anti-IL-5 treatment should be used
only in patients with severe asthma (GINA step 4/5).
However, subgroup analyses showed that among
patients receiving ICS plus a long-acting b2-agonist,
the effect of reslizumab on exacerbations was compar-
able to all the included patients, e.g. patients receiving
ICS with or without a long-acting b2-agonist.
The blood eosinophil count threshold for inclusion
was higher in the reslizumab studies compared to the
mepolizumab studies. The majority of reslizumab stu-
dies included patients with ≥400 eosinophils per
microL, and one study included patients with ≥ 3%
sputum eosinophils, whereas the mepolizumab studies
included patients with ≥150–300 eosinophils per
microL depending on the time of measurement. This
could indicate that the reslizumab-treated patients suf-
fered from a more eosinophil-driven disease. However,
the number of previous exacerbations was higher in the
mepolizumab vs. reslizumab studies, which is a predic-
tor of a good response to anti-IL-5 treatment.
Limitations
Assessment of differences in efficacy and adverse
events of mepolizumab and reslizumab was only pos-
sible using indirect comparison by Bucher’s method for
aggregated data as no head-to-head studies were avail-
able. This method is prone to produce more uncertain
results due to the difference in inclusion criteria and
design of the different studies.
It is a limitation that only data on mepolizumab and
only from one study were available with reduction in
daily OCS use as primary outcome [25]. Furthermore,
that study did not provide data on the predefined
critical outcome ‘Percentage of patients who discontin-
ued OCS’. Due to this, the Expert Committee defined
the outcome measure ‘Percentage of patients who
achieve a ≥50% reduction in OCS dose’ after the pro-
tocol had been approved by the Danish Medicines
Council.
An important limitation not discussed in previous
reviews of anti-IL-5 treatment is the external validity.
The drugs are expensive, and at present, initiation of
anti-IL-5 treatment should not be considered for
patients not optimally treated according to GINA or
other recognised international asthma guidelines.
Unfortunately, clinical assessment prior to inclusion is
not described in detail in any of the available studies.
This is of utmost importance as it is now widely
acknowledged that systematic assessment of asthma
phenotype, triggers, comorbidities, and obstacles to
asthma control to differentiate between difficult-to-
treat asthma and severe asthma is needed to increase
asthma control and prevent initiation of irrelevant
expensive treatments [37–39]. In England, the
National Health Service (NHS) has established specia-
lised respiratory services to centralise the systematic
assessment of difficult-to-treat-asthma in adults to
improve outcomes for people with severe asthma and
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to act as clinical gatekeepers to ensure appropriate
access to high-cost technologies [40].
Finally, it can be speculated that the impact of anti-IL-5
treatment would be even more pronounced in patients
with absent asthma control exclusively due to eosinophilic
inflammation, similarly to the observed improvement in
outcomes since the first negative studies in patients, which
were not selected based on blood or sputum eosinophil
counts [41]. Indeed, the subgroup analyses suggested a
more pronounced effect in patients with higher eosinophil
counts, a higher exacerbation rate at enrolment, and
among patients on GINA step 5 treatment. Based on
our results, prescribing anti-IL-5 treatment with either
mepolizumab or reslizumab to patients correctly diag-
nosed with severe eosinophilic asthma according to pub-
lished clinical guidelines [3] seems cost-effective as it will
significantly reduce exacerbation rate and hospitalizations
and may alleviate OCS-related systemic side effects.
Conclusions
Mepolizumab and reslizumab provide significant and
clinically relevant improvement in exacerbation rate
and OCS reduction, whereas improvement in FEV1,
asthma control, and asthma-related quality of life is
below MCIDs. Indirect inter-study comparisons revealed
no differences between the anti-IL-5 drugs in efficacy or
safety measures, whilst differences in OCS reduction
could not be investigated due to the lack of reslizumab
studies with this outcome. Neither of the available stu-
dies incorporated novel standards of systematic assess-
ment of difficult-to-treat asthma prior to onset of
treatment. To optimise use of healthcare resources, an
increasing focus on systematic assessment to differentiate
difficult-to-treat asthma from severe asthma before com-
mencing biological agents is developing.
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